Delayed administration of elezanumab, a human anti-RGMa neutralizing monoclonal antibody, promotes recovery following cervical spinal cord injury
Autor: | Mothe, Andrea J., Jacobson, Peer B., Caprelli, Mitchell, Ulndreaj, Antigona, Rahemipour, Radmehr, Huang, Lili, Monnier, Philippe P., Fehlings, Michael G., Tator, Charles H. |
---|---|
Zdroj: | In Neurobiology of Disease 1 October 2022 172 |
Databáze: | ScienceDirect |
Externí odkaz: |